Abstract 3199

Poster Board III-136

Differences between hypoplastic MDS (h-MDS) and aplastic anemia (AA) are not defined. Role of karyotype and fluorescent in situ hybridization (FISH) in these diseases is not established.

Medical record review at Seoul National University Hospital between 1990 and 2008 was performed. Patients diagnosed as either h-MDS or AA based on morphology was reviewed. We assessed overall survival (OS) and leukemic conversion.

369 AA and 40 h-MDS patients (median age 39 years, range 15-82) were analyzed. 235 and 165 patients underwent karyotyping and FISH at diagnosis respectively. Compared to AA, karyotypic abnormality, 5q deletion, trisomy 8 and trisomy 1q FISH abnormalities were more frequently found in h-MDS. Median OS of h-MDS was shorter than AA (60 vs. 219 months, p<0.001) with prognosis of h-MDS falling between severe and very severe AA. Patients with h-MDS had more frequent leukemic conversion (p<0.001) than AA patients. Karyotypic abnormality was not prognostic in AA (p=0.225). For h-MDS, complex karyotype and trisomy 1q FISH abnormality predicted poor prognosis.

The prognosis of h-MDS falls between severe and very severe AA. h-MDS accompanies frequent karyotypic and FISH abnormality and is prone to leukemic conversion. Complex karyotype and trisomy 1q FISH abnormality may have a prognostic role in h-MDS.

Table 1

Characteristics of patients according morphologic classification in 409 patients

CharacteristicsAplastic anemia (N=369)Hypoplastic MDS (N=40)p-value
Age (median) 38.0 49.5 0.005 
Gender   0.846 
Male 197 22  
Female 172 18  
White blood cell (mean) (/μL) 2724 3042 0.368 
Reticulocyte count (mean) (%) 1.1 1.8 0.007 
Hemoglobin (mean) (g/dL) 8.3 7.9 0.357 
Platelet (mean) (/μL) 44130 109000 0.008 
Severity of cytopenia*   0.007 
Moderate 244 36  
Severe 96  
Very severe 28  
PNH component   NA 
Present 15 NA  
Absent 351 NA  
IPSS risk category   NA 
Intermediate-1 NA 25  
Intermediate-2 NA  
High NA  
Oxymetholone administration#   0.005 
Yes 167  
No 196 30  
Immunosuppressive treatment#   0.005 
Yes 114  
No 249 35  
Stem cell transplantation#   1.000 
Yes 49  
No 314 34  
CharacteristicsAplastic anemia (N=369)Hypoplastic MDS (N=40)p-value
Age (median) 38.0 49.5 0.005 
Gender   0.846 
Male 197 22  
Female 172 18  
White blood cell (mean) (/μL) 2724 3042 0.368 
Reticulocyte count (mean) (%) 1.1 1.8 0.007 
Hemoglobin (mean) (g/dL) 8.3 7.9 0.357 
Platelet (mean) (/μL) 44130 109000 0.008 
Severity of cytopenia*   0.007 
Moderate 244 36  
Severe 96  
Very severe 28  
PNH component   NA 
Present 15 NA  
Absent 351 NA  
IPSS risk category   NA 
Intermediate-1 NA 25  
Intermediate-2 NA  
High NA  
Oxymetholone administration#   0.005 
Yes 167  
No 196 30  
Immunosuppressive treatment#   0.005 
Yes 114  
No 249 35  
Stem cell transplantation#   1.000 
Yes 49  
No 314 34  

Figure 1

OS of patients according to disease subtype h-MDS had inferior OS compared to AA in general (A), and its prognosis falls between SAA and VSAA (B). h-MDS had shorter OS compared to AA even stratified by the degree of cytopenia. IPSS score had a prognostic impact on h-MDS (D).

Figure 1

OS of patients according to disease subtype h-MDS had inferior OS compared to AA in general (A), and its prognosis falls between SAA and VSAA (B). h-MDS had shorter OS compared to AA even stratified by the degree of cytopenia. IPSS score had a prognostic impact on h-MDS (D).

Close modal
Disclosures

No relevant conflicts of interest to declare.

Author notes

*

Asterisk with author names denotes non-ASH members.

Sign in via your Institution